Optimizing Oncology Rhyme Workflows for Complex Cancer Care

Klivira streamlines oncology rhyme workflows, transforming prior authorization for high-volume, high-complexity cancer treatments and ensuring timely patient access.

Oncology prior authorization (PA) represents one of healthcare's most intricate and high-stakes administrative challenges. Revenue cycle directors and prior authorization coordinators in cancer care face immense pressure to navigate frequent regimen changes, high-cost therapies, and urgent treatment starts. Klivira’s platform is engineered to automate and optimize these complex oncology rhyme processes.

The Unique Demands of Oncology Prior Authorization

Cancer care pathways are characterized by a high cadence of PA events per patient, often exceeding 10–20 over a treatment course. This stems from the need for approvals across diagnosis, staging, treatment initiation, regimen modifications due to progression or toxicity, supportive care, and surveillance. Automation is critical to manage this volume without compromising the urgency of care.

Key Prior Authorization Triggers in Oncology

**J-code chemotherapy and biologic infusions:** Approvals for IV chemotherapy, immunotherapies, and targeted therapies.
**Advanced imaging:** PET/CT, advanced MRI, and molecular imaging for staging and surveillance.
**Radiation oncology procedures:** IMRT, IGRT, SBRT, brachytherapy, and proton-beam therapy.
**Genetic and molecular testing:** NGS panels and single-gene tests for treatment selection and risk stratification.
**Specialty oral oncolytics:** Oral chemotherapy and targeted therapies, often requiring pharmacy benefit PA.
**Supportive care medications:** Growth factors, antiemetics, and bone-targeting agents.

Navigating Documentation and Clinical Guidelines with Automation

The NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium serve as the primary medical-necessity frameworks for oncology PA. Klivira’s platform integrates NCCN-compendium-aware policy logic to surface required documentation—such as pathology reports, tumor staging, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), and performance status (ECOG/Karnofsky)—at the point of order entry. This proactive approach ensures comprehensive submissions aligned with payer requirements.

Mitigating Common Oncology PA Denials

Oncology PA denials frequently arise from off-label use without compendium support, step therapy requirements, documentation gaps, and site-of-service mismatches. Klivira's automation helps mitigate these by validating submissions against payer rules and clinical guidelines pre-submission, identifying potential denial triggers, and facilitating the necessary documentation collection to support medical necessity, including for off-label indications with appropriate compendium citations.

Seamless Handling of Medical vs. Pharmacy Benefit Split

Oncology drugs are split between medical benefit (IV infusions, injections) and pharmacy benefit (oral oncolytics). Klivira's platform intelligently routes medical-benefit PAs through appropriate payer channels (e.g., X12 278 or payer portals) and pharmacy-benefit PAs through PBMs and ePA partners. This dual-pathway management is critical for comprehensive oncology rhyme automation, ensuring all necessary approvals are pursued via the correct administrative route.

EMR Integration and Payer Touchpoints for Oncology Workflows

Klivira integrates directly with leading EMRs via SMART on FHIR, capturing order types for chemotherapy regimens, advanced imaging, and specialty oral oncolytics at the point of care. This integration automates the initiation of PA requests, pre-populates forms with patient data, and facilitates secure communication with payer portals. For clinical-necessity denials that commonly route to peer-to-peer review, Klivira supports scheduling integration to streamline oncologist-payer interactions, improving PA cycle times.

Frequently asked questions

How does Klivira address the urgency of treatment starts in oncology?

Klivira streamlines the oncology rhyme process by automating documentation gathering and submission, reducing manual delays. This accelerated workflow helps minimize diagnosis-to-treatment intervals, which is critical for many aggressive cancer types, by proactively addressing PA requirements.

Can Klivira handle regimen-level prior authorizations for combination therapies?

Yes, Klivira is designed for regimen-level PA workflows. Our system bundles related components of complex oncology regimens (e.g., chemotherapy + targeted therapy + immunotherapy) into single submissions where payer policies allow, and intelligently manages separate submissions when required, ensuring comprehensive coverage.

How does Klivira support compliance with NCCN guidelines for oncology PA?

Klivira incorporates NCCN-compendium-aware policy logic. This means our platform can guide users on required documentation based on specific tumor types, lines of therapy, and molecular markers, ensuring submissions align with the dominant medical-necessity frameworks used by payers.

What is Klivira's approach to managing the medical vs. pharmacy benefit split for oncology drugs?

Klivira automatically identifies whether an oncology drug falls under the medical or pharmacy benefit. It then routes the PA request through the appropriate channel – either via X12 278 and payer portals for medical benefit drugs or through PBMs and ePA partners for oral oncolytics, ensuring correct and efficient processing.

Does Klivira assist with peer-to-peer reviews for oncology denials?

Yes, Klivira recognizes the prevalence of peer-to-peer reviews for clinical-necessity denials in oncology. Our platform includes features that support the scheduling and tracking of these critical oncologist-payer interactions, helping to expedite the appeal process.